HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
2025-09-17
Employee Stock Ownership
Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments
Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities